A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Key facts

Sponsor

Verastem, Inc.

Principal Investigator

Rachel Grisham, MD

GOG Foundation

Intervention

avutometinib(drug)

Enrollment

270 enrolled

Eligibility

18 years · FEMALE

Timeline

2024 – 2031

Study locations (30)

• HonorHealth, Phoenix, Arizona, United States
• University of Arkansas, Little Rock, Arkansas, United States
• UCLA Health, Los Angeles, California, United States
• UC Davis, Sacramento, California, United States
• University of California, San Francisco, San Francisco, California, United States
• Yale University, New Haven, Connecticut, United States
• Florida Cancer Specialists - South, Fort Myers, Florida, United States
• Mount Sinai, Miami Beach, Florida, United States
• AdventHealth, Orlando, Florida, United States
• Moffitt Cancer Center, Tampa, Florida, United States
• Florida Cancer Specialists Research East, West Palm Beach, Florida, United States
• Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
• NorthShore University HealthSystem, Evanston, Illinois, United States
• Louisiana State University, New Orleans, Louisiana, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

GOG Foundation · European Network of Gynaecological Oncological Trial Groups (ENGOT) · Australia New Zealand Gynaecological Oncology Group · Korean Gynecologic Oncology Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07508306
  Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity
  Faculty of Medicine of Tunis
• RECRUITINGPHASE1NCT07524322
  Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  Regor Pharmaceuticals Inc.
• RECRUITINGPHASE1NCT06366490
  Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
  PhotonPharma, Inc.
• RECRUITINGPHASE1NCT07402915
  Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
  AstraZeneca
• RECRUITINGNANCT07280312
  Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
  Mayo Clinic
• RECRUITINGPHASE2NCT07158021
  Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
  University of Michigan Rogel Cancer Center
• RECRUITINGPHASE2NCT06971744
  Autophagy Maintenance (AUTOMAIN)
  Medical University of South Carolina
• RECRUITINGPHASE3NCT07544030
  A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
  tongweihua

See all trials for Malignant epithelial tumor of ovary →